16 mar: Lundbeck/CEO: Nytilkøbt lægemiddelkandidat har milliardpotentiale
16 mar: Bavarian får kontrakt hos USA's forsvar - værdi kan runde 200 mio..
16-03-2018 13:54:13

Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus

Relateret indhold
17:04 - 
Torsdagens aktier: Pandora og Ørsted trak C25 i rødt
11:39 - 
Aktier/middag: Pandora og Ørsted trækker C25 i rødt
09:29 - 
Aktier/åbning: Ørsted og Pandora får tæsk i negativ C25..
Relateret debat
17:34 - 
Det ser godt ud. Prostvac er ikke en fejl. Bare en star..
17:25 - 
  Har købt bava til kurs ca 207 da denne ne..
17:11 - 
Hvorfor skulle den ikke holde i morgen?

  • Collaboration valued up to $36M

  • Multivalent vaccine designed to protect humans against Eastern, Venezuelan, and Western equine encephalitis virus

COPENHAGEN, Denmark, March 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of a new alliance with the United States Department of Defense (DoD) for the development of a prophylactic vaccine against the equine encephalitis virus-a rare, but potentially deadly mosquito-borne illness. With funding from the DoD, Bavarian Nordic will utilize its proprietary MVA-BN® platform to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available.

An MVA-BN® based candidate vaccine targeting three separate equine encephalitis viruses including Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV) has already demonstrated efficacy against all three viruses in preclinical models. The multi-year collaboration will include further preclinical studies to support clinical development, GMP production and establishment of safety and immunogenicity in humans. Clinical proof of concept data will warrant further development of the MVA-BN® based candidate vaccine with potential follow-on funding towards FDA licensure and production. The vaccine would then be available to the DoD as needed to vaccinate individuals who may be deployed in a region considered at high risk for a particular illness.

The agreement includes total potential considerations of approximately US$36 million. The award of this multi-year contract does not change the Company's financial guidance for 2018.  

"We are very proud of this alliance which represents yet another public/private engagement between Bavarian Nordic and the U.S. government, and provides the Department of Defense with the first in what could become a 'library' of safe, clinically validated vaccines that are readily accessible and can be deployed as needed," said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. "This type of collaboration further validates our model for preparedness, which could prove useful in the years to come for this, and potentially other rare and tropical diseases."

About Equine Encephalitis Viruses

Eastern, Venezuelan and Western equine encephalitis virus belong to the family alphavirus, and are transmitted through mosquitos, as well as birds and some mammals. While the viruses vary in infection rates and severity of disease, all three pathogens are associated with risks of flu-like symptoms, potential central nervous disorders, and death. All three viruses are also considered as potential biological threats, having been investigated as potential biological weapons at various times in the past century. 

Federal funding acknowledgment

This project will be funded in whole or in part with federal funds under an Other Transaction Authority agreement with U.S. Army Contracting Command-New Jersey through the Medical CBRN Defense Consortium, contract MCDC-17-04-001/2018-315

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 09 / 2018

2018-09-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2018-09-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 maj
BAVA
Som lovet ville jeg vende tilbage i kurs 210. Tillykke til alle. Jeg holder. Kurs 250-260 kommer sna..
9
14:28
BAVA
Vi er ved spørgsmål nu.. de forventer 120 mio USD for beviseret på Kopper...
6
18 maj
BAVA
jeg tror den stiger når USA åbner, der er flere gode nyheder
6
14:33
BAVA
Der diskuteres med forskellige partner på RSV - ingen afklaring pt...
5
14:30
BAVA
Der er dialog med WHO om at bruge Janssen/Bavarians produkt ved Ebola..
5
20 maj
BAVA
Jeg har forøget kraftig i 180 og 170, jeg sælger ikke på dette niveau. Selvfølldig vilnjeg gerne hav..
5
18 maj
BAVA
Vi hæver i dag anbefalingen på Bavarian Nordic til Køb fra Hold med kursmål DKK 290. Det svarer til ..
5
11:17
BAVA
Jeg hæfter mig specielt ved, at han omkring 3:30 nævner, at der også er godt nyt i kulissen, som han..
4
09:11
BAVA
Jammen det er da utroligt - deres resultat er det som de har lovet markedet også er I nogle som kriv..
4
22 maj
BAVA
Shorterne kaster aktien - de får den ikke ned i 150 som de håbede. Kurs 220-225 er lige om hjørnet, ..
4

Hartmann Q1: Sætter gang i effektiviseringsprogram for at nå 2018-mål

24-05-2018 14:29:06
Fremgang i emballagesalget og et højere teknologisalg prægede årets første kvartal hos emballageproducenten Brødrene Hartmann, der kom ud af perioden med en stigning i både omsætningen og indtjeningen.I første kvartal omsatte virksomheden for 624 mio. kr. mod 572 mio. kr. i samme periode af 2017, og fremgangen kom, på trods af at valutakurser påvirkede omsætningen i år med 55 mio. kr. Det fremgår ..

Pandora/Carnegie: Ser nedjustering komme senere på året

24-05-2018 09:59:22
Smykkekoncernen Pandora har kurs mod en nedjustering senere på året, vurderer Carnegie, som skærer gevaldigt i kursmålet for aktie til 400 kr. fra før 700 kr. og sænker anbefalingen til "sælg" fra "hold". Finanshusets Pandora-analytiker, Lars Topholm, peger også på, at det kan blive nødvendigt at få nye kræfter ind til at få gennemført de nødvendige ændringer i selskabet og genskabe tilliden. Regn..

TCM: Kapitalfond har solgt alle aktier seks måneder efter børsnotering

24-05-2018 08:35:40
Majoritetsaktionæren Innovator International, der ejes af kapitalfonden IK Investment Partners, har solgt alle sine aktier i den danske køkkenkoncern TCM Group.Salget af de i alt 1,97 mio. aktier er solgt gennem en accelereret bookbuiding-proces til institutionelle investorer for 98 kr. per aktie, skriver Bloomberg News.Torsdag er det præcist seks måneder siden, at TCM Group havde første handelsda..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Carnegie: Ser nedjustering komme senere på året
2
Bavarian Q1: Lav omsætning giver trecifret millionunderskud
3
Pandora/Carnegie: Sænker anbefalingen til "sælg" fra "hold" - NY
4
Aktier/tendens: Ørsted kan blive presset af nederlag i USA
5
Norwegian suser til vejrs efter historie om Ryanair-interesse

Relaterede aktiekurser

Bavarian Nordic A/S 209,30 1,7% Stigning i aktiekurs
Bavarian Nordic Ord Shs 206,80 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2018 17:46:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180524.2 - EUROWEB2 - 2018-05-24 17:46:34 - 2018-05-24 17:46:34 - 1 - Website: OKAY